A phase 3, multi-centre, randomised, double-blinded trial of favipiravir versus placebo for treatment of mild Covid-19 in outpatients in South Africa (FATE Trial)
- Funded by Department of Science and Innovation - South Africa
- Total publications:0 publications
Grant search
Key facts
Disease
COVID-19Start & end year
N/AKnown Financial Commitments (USD)
$140,000Funder
Department of Science and Innovation - South AfricaResearch Location
South AfricaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Phase 3 clinical trialSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IIIBroad Policy Alignment
PendingAge Group
Adults (18 and older)Vulnerable Population
UnspecifiedOccupations of Interest
Unspecified